# International Urology Cancer Summit

> International Urology Cancer Summit, Portsmouth, 4th & 5th September 2025


## Posts

- [IUC23530-78](https://urologycancersummit.org/iuc23530-78/)
- [IUC24426-83](https://urologycancersummit.org/iuc24426-83/)
- [IUC24425-82](https://urologycancersummit.org/iuc24425-82/)
- [IUC24404-79](https://urologycancersummit.org/iuc24404-79/)
- [IUC24380-82](https://urologycancersummit.org/iuc24380-82/)
- [IUC23534-82](https://urologycancersummit.org/iuc23534-82/)
- [IUC22936-87](https://urologycancersummit.org/iuc22936-87/)
- [IUC24413-79](https://urologycancersummit.org/iuc24413-79/)
- [IUC23424-80](https://urologycancersummit.org/iuc23424-80/)
- [IUC24427-84](https://urologycancersummit.org/iuc24427-84/)
- [IUC24432-80](https://urologycancersummit.org/iuc24432-80/)
- [IUC24424-81](https://urologycancersummit.org/iuc24424-81/)
- [IUC24412-78](https://urologycancersummit.org/iuc24412-78/)
- [IUC24409-84](https://urologycancersummit.org/iuc24409-84/)
- [IUC24408-83](https://urologycancersummit.org/iuc24408-83/)
- [IUC24403-78](https://urologycancersummit.org/iuc24403-78/)
- [IUC24400-75](https://urologycancersummit.org/iuc24400-75/)
- [IUC24396-89](https://urologycancersummit.org/iuc24396-89/)
- [IUC24392-85](https://urologycancersummit.org/iuc24392-85/)
- [IUC23438-85](https://urologycancersummit.org/iuc23438-85/)
- [IUC24434-82](https://urologycancersummit.org/iuc24434-82/)
- [IUC24433-81](https://urologycancersummit.org/iuc24433-81/)
- [IUC24421-78](https://urologycancersummit.org/iuc24421-78/)
- [IUC24406-81](https://urologycancersummit.org/iuc24406-81/)
- [IUC24405-80](https://urologycancersummit.org/iuc24405-80/)
- [IUC24402-77](https://urologycancersummit.org/iuc24402-77/)
- [IUC24398-91](https://urologycancersummit.org/iuc24398-91/)
- [IUC24397-90](https://urologycancersummit.org/iuc24397-90/)
- [IUC24025-78](https://urologycancersummit.org/iuc24025-78/)
- [IUC23262-80](https://urologycancersummit.org/iuc23262-80/)
- [IUC23223-77](https://urologycancersummit.org/iuc23223-77/)
- [IUC23442-80](https://urologycancersummit.org/iuc23442-80/)
- [IUC24428-85](https://urologycancersummit.org/iuc24428-85/)
- [IUC24419-85](https://urologycancersummit.org/iuc24419-85/)
- [IUC23448-86](https://urologycancersummit.org/iuc23448-86/)
- [IUC24414-80](https://urologycancersummit.org/iuc24414-80/)
- [IUC24394-87](https://urologycancersummit.org/iuc24394-87/)
- [IUC24360-80](https://urologycancersummit.org/iuc24360-80/)
- [IUC24358-87](https://urologycancersummit.org/iuc24358-87/)
- [IUC22940-82](https://urologycancersummit.org/iuc22940-82/)
- [IUC24415-81](https://urologycancersummit.org/iuc24415-81/)
- [IUC24429-86](https://urologycancersummit.org/iuc24429-86/)
- [IUC24422-79](https://urologycancersummit.org/iuc24422-79/)
- [IUC22370-79](https://urologycancersummit.org/iuc22370-79/)
- [IUC24431-79](https://urologycancersummit.org/iuc24431-79/)
- [IUC24420-77](https://urologycancersummit.org/iuc24420-77/)
- [IUC24418-84](https://urologycancersummit.org/iuc24418-84/)
- [IUC24417-83](https://urologycancersummit.org/iuc24417-83/)
- [IUC24411-77](https://urologycancersummit.org/iuc24411-77/)
- [IUC24410-76](https://urologycancersummit.org/iuc24410-76/)
- [IUC24390-83](https://urologycancersummit.org/iuc24390-83/)
- [IUC22021-72](https://urologycancersummit.org/iuc22021-72/)
- [Novel prognostic score for patients with metastatic bladder cancer on immunotherapy using real-world data](https://urologycancersummit.org/novel-prognostic-score-for-patients-with-metastatic-bladder-cancer-on-immunotherapy-using-real-world-data/)
- [Efficacy and toxicity of half dose BCG therapy in bladder cancer](https://urologycancersummit.org/efficacy-and-toxicity-of-half-dose-bcg-therapy-in-bladder-cancer/)
- [External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy](https://urologycancersummit.org/external-validation-of-the-novel-prognostic-meet-uro-score-in-metastatic-renal-cell-carcinoma-on-first-line-immune-combination-therapy/)
- [Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study](https://urologycancersummit.org/clinical-parameters-for-first-line-immuno-combinations-choice-in-metastatic-renal-cell-carcinoma-mrcc-patients-pts-the-meet-uro-33-study/)
- [Baseline characteristics as parameters of choice of first-line therapy in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study](https://urologycancersummit.org/baseline-characteristics-as-parameters-of-choice-of-first-line-therapy-in-metastatic-renal-cell-carcinoma-mrcc-patients-pts-the-meet-uro-33-study/)
- [Clinical response of advanced renal carcinoma’s patients treated with small immunomodulatory proteolipid particle](https://urologycancersummit.org/clinical-response-of-advanced-renal-carcinomas-patients-treated-with-small-immunomodulatory-proteolipid-particle/)
- [External validation of the Grade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma](https://urologycancersummit.org/external-validation-of-the-grade-age-nodes-and-tumor-grant-score-for-patients-with-surgically-treated-papillary-renal-cell-carcinoma/)
- [Adopting the Sectra Lesion Tracking Tool for RECIST 1.1 in Renal Cell Cancer patients: First in the UK Pilot Study](https://urologycancersummit.org/adopting-the-sectra-lesion-tracking-tool-for-recist-1-1-in-renal-cell-cancer-patients-first-in-the-uk-pilot-study/)
- [The prognostic impact of the metastatic pattern in advanced Renal Cell Carcinoma (aRCC): a retrospective analysis of 306 patients (pts) treated with compassionate ipilimumab and nivolumab (IPI+NIVO)](https://urologycancersummit.org/the-prognostic-impact-of-the-metastatic-pattern-in-advanced-renal-cell-carcinoma-arcc-a-retrospective-analysis-of-306-patients-pts-treated-with-compassionate-ipilimumab-and-nivolumab-ipinivo/)
- [Real word data of first-line metastatic renal cell carcinoma (mRCC) treatment choice in a tertiary centre in the UK](https://urologycancersummit.org/real-word-data-of-first-line-metastatic-renal-cell-carcinoma-mrcc-treatment-choice-in-a-tertiary-centre-in-the-uk/)
- [Carboplatin AUC10 in metastatic Seminoma  (Topic: "Real world evidence (except case studies)")](https://urologycancersummit.org/carboplatin-auc10-in-metastatic-seminoma-topic-real-world-evidence-except-case-studies/)
- [Remote Consultation in Prostate Cancer Clinics: Impact on Carbon Footprint and Patient Satisfaction](https://urologycancersummit.org/remote-consultation-in-prostate-cancer-clinics-impact-on-carbon-footprint-and-patient-satisfaction/)
- [Serum levels of Thymidine Kinase 1 correlate with PSA and tumour shrinkage in metastatic Hormone Sensitive Prostate Cancer (mHSPC)](https://urologycancersummit.org/serum-levels-of-thymidine-kinase-1-correlate-with-psa-and-tumour-shrinkage-in-metastatic-hormone-sensitive-prostate-cancer-mhspc/)
- [Transcriptomic Analysis of Patients with Metastatic Hormone-Sensitive Prostate Cancer to Identify Genomic Signatures Involved in the Transition from Androgen-Dependent to Androgen-Independent Phenotype](https://urologycancersummit.org/transcriptomic-analysis-of-patients-with-metastatic-hormone-sensitive-prostate-cancer-to-identify-genomic-signatures-involved-in-the-transition-from-androgen-dependent-to-androgen-independent-phenotyp/)
- [Prostate-Specific Membrane Antigen PET-CT findings in biochemical relapse after prostatectomy](https://urologycancersummit.org/prostate-specific-membrane-antigen-pet-ct-findings-in-biochemical-relapse-after-prostatectomy/)
- [A case of brain metastasis development despite PSA suppression in a hormone sensitive metastatic prostate cancer patient under apalutamide treatment](https://urologycancersummit.org/a-case-of-brain-metastasis-development-despite-psa-suppression-in-a-hormone-sensitive-metastatic-prostate-cancer-patient-under-apalutamide-treatment/)
- [Evaluating Outcome and Prognostic Factors in Low-Volume Stage IV Hormone-Sensitive Prostate Cancer (mHSPC)](https://urologycancersummit.org/evaluating-outcome-and-prognostic-factors-in-low-volume-stage-iv-hormone-sensitive-prostate-cancer-mhspc/)
- [Southampton experience of prostate specific membrane antigen therapy for metastatic prostate cancer](https://urologycancersummit.org/southampton-experience-of-prostate-specific-membrane-antigen-therapy-for-metastatic-prostate-cancer/)
- [Real-life Analysis of [177Lu]Lu-PSMA-617 on mCRPC Patients cohort treated in France](https://urologycancersummit.org/real-life-analysis-of-177lulu-psma-617-on-mcrpc-patients-cohort-treated-in-france/)
- [Prostate cancer (PC) and homologous recombination repair genes mutations (HRRm): a retrospective, monocentric, observational study aimed at recording histopathological and clinical data and their associations with oncological outcomes.](https://urologycancersummit.org/prostate-cancer-pc-and-homologous-recombination-repair-genes-mutations-hrrm-a-retrospective-monocentric-observational-study-aimed-at-recording-histopathological-and-clinical-data-and-their-asso/)

## Pages

- [Live Stream 2](https://urologycancersummit.org/live-stream-2/)
- [Mini Orals 2025](https://urologycancersummit.org/mini-orals-2025/)
- [Live Stream 2025](https://urologycancersummit.org/live-stream-2025/)
- [5th September 2025](https://urologycancersummit.org/5th-september-2025/)
- [Abstracts 2025](https://urologycancersummit.org/abstracts-2025/)
- [4th September 2025](https://urologycancersummit.org/4th-september-2025/)
- [Sponsors 2025](https://urologycancersummit.org/sponsors-2025/)
- [Congress Venue](https://urologycancersummit.org/congress-venue/)
- [Programme 2025](https://urologycancersummit.org/programme-2025/)
- [Live Stream 2024](https://urologycancersummit.org/live-stream-2024/)
- [Industry Symposia 2024](https://urologycancersummit.org/https-urologycancersummit-org-programme-2024/)
- [Abstracts 2024](https://urologycancersummit.org/abstracts-2024/)
- [Abstracts](https://urologycancersummit.org/abstracts/)
- [Programme 2024](https://urologycancersummit.org/programme-2024/)
- [Live Stream 2023](https://urologycancersummit.org/live-stream-2023/)
- [Site map](https://urologycancersummit.org/site-map/)
- [Registration](https://urologycancersummit.org/registration/)
- [Sponsors](https://urologycancersummit.org/sponsors/)
- [Programme 2023](https://urologycancersummit.org/programme-2023/)
- [Privacy Policy](https://urologycancersummit.org/privacy-policy/)
- [Home](https://urologycancersummit.org/)


[comment]: # (Generated by Hostinger Tools Plugin)